Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.
The COVID-19 pandemic accelerated many changes in the pharmacy field, but maintaining that momentum and working together will be essential for the future growth of pharmacy.
The FDA initially approved baloxavir marboxil in October 2018 for the treatment of acute, uncomplicated influenza.
Doug Long and Scott Biggs of IQVIA discussed how data from Australia can help predict the strength of the upcoming flu season.
Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses why pharmacy technicians are leaving the profession and why they are staying.
Students from the Daniel K. Inouye College of Pharmacy discuss their experience at the University of Hawaii.
Patients who had previously hit their out-of-pocket maximums could see a significant change.
Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses how pharmacists and pharmacy technicians can advocate for the certification of pharmacy technicians.
Scott Biggs and Doug Long of IQVIA discussed where the pharmacy industry stands now and what they predict for the future.
Although it may not have immediate significant impacts for many patients, the Inflation Reduction Act could open the door for future changes.
Rina Shah, PharmD, discussed the growing role for pharmacists in encouraging holistic health and wellness for patients.
Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses how pharmacy technicians can face burnout and advocate for themselves.
A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).
Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).
Paul Forsberg, PharmD, BCOP, MHA, director of Pharmacy Services at Minnesota Oncology discusses how pharmacists can remain on top of shifts in the nature of biosimilar payer benefit design.
Desmond Hunt, PhD, senior principal scientist at US Pharmacopeia (USP), discusses the standards and resources that USP has recently published or is looking at now on the subject of pharmacy in transit.
Although innovation in the pharmacy space is continuing nearly 3 years into the COVID-19 pandemic, provider status and reimbursement are both necessary to continue this innovation in the future.
In addition to garnering more public awareness in recent years, expert Michael Zimmerman said supply chain disruptions have “hyper-evolved” during the COVID-19 pandemic.
Although pharmacies have repeatedly proven their value and continue to be essential to providing equitable health care, Jason Ausili, PharmD, said commensurate reimbursement is necessary to move forward.
At the National Association of Chain Drug Stores (NACDS) 2022 Total Store Expo, Pharmacy Times spoke with Danny Sanchez, senior vice president and general manager of EnlivenHealth.
Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.
Expanding technician roles may lead to improved efficacy in the workplace and alleviate burdens overwhelming pharmacists.
The panel of experts share personal experiences with burnout in the pharmacy setting and outline opportunities for improving the atmosphere of the workplace.
George Rafferty and Jason Dinger of AmerisourceBergen discuss the investment interests of the venture capital fund AB Health Ventures within the retail pharmacy space.
Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.
Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).
Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses the stigma around drug diversion and the best ways to address and fight that stigma.
Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.
Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses his experience with drug diversion and addiction.
The Total Store Expo is taking place in Boston from August 27 through 29, 2022.
